NCT06451705

Brief Summary

Studied the comparison between PECS II block and LIA on pain intensity, opioid requirements, RNL, and postoperative IL-6 levels in MRM patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2024

Completed
23 days until next milestone

First Submitted

Initial submission to the registry

May 23, 2024

Completed
19 days until next milestone

First Posted

Study publicly available on registry

June 11, 2024

Completed
Last Updated

June 11, 2024

Status Verified

June 1, 2024

Enrollment Period

2 months

First QC Date

May 23, 2024

Last Update Submit

June 4, 2024

Conditions

Keywords

postoperative painmodified radical mastectomyperipheral nerve blocklocal infiltration anesthesiapectoralis nerve block

Outcome Measures

Primary Outcomes (4)

  • Concentration of Plasma Interleukin-6

    in pg/dL

    1 hour before surgery, 2 hour after surgery, 12 hour after surgery

  • Neutrophil-lymphocyte ratio

    Neutrophil divided by lymphocyte

    1 hour before surgery, 2 hour after surgery, 12 hour after surgery

  • Pain intensity (Using Numeric Rating Scale)

    Scale from 0-10, lower score = better outcome

    hour 0, 2, 4, 6, 12, 24

  • Rescue opioid requirement

    Using fentanyl at a dose of 0.5-1 μg/kg/IV titrated as needed, in mcg (given if the patient had NRS of \>4/10)

    Within 24 hours after surgery

Secondary Outcomes (3)

  • Demographic baseline data

    baseline (before the surgery)

  • Time until first rescue opioid requirement

    Within 24 hours after surgery

  • Nausea and vomiting

    Within 24 hours after surgery

Study Arms (2)

PECS

ACTIVE COMPARATOR

PECS II block before surgery using isobaric bupivacaine 0.25% 20 mL (50 mg)

Drug: PECS II block

LIA

ACTIVE COMPARATOR

Local infiltration anesthesia after completion of surgery using isobaric bupivacaine 0.25% 20 mL (50 mg)

Drug: LIA

Interventions

Treatment group that received the PECS II block using isobaric bupivacaine 0.5% 50 mg

PECS
LIADRUG

Treatment group that received the local infiltration anesthesia using isobaric bupivacaine 0.5% 50 mg

LIA

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Age: 18-60 years old.
  • Body weight (BW): 50-70 kg.
  • Height (TB): 150-170 cm.
  • Body mass index (BMI): 18.5-29.9 kg/m2.
  • American Society of Anesthesiologists physical status (ASA PS) class I-II.
  • Patients undergoing elective MRM surgery under general anesthesia.

You may not qualify if:

  • Patients with contraindications to PECS II block.
  • Patients with contraindications to LIA.
  • Patients with coagulation disorders or receiving anticoagulant therapy.
  • Patients with a history of chronic pain.
  • Patients with a history of allergy to study materials.
  • Patients with a history of previous breast surgery.
  • Patient refuses to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

RSUP dr. Wahidin Sudirohusodo

Makassar, South Sulawesi, 90173, Indonesia

Location

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: single-blind randomized trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 23, 2024

First Posted

June 11, 2024

Study Start

March 1, 2024

Primary Completion

April 30, 2024

Study Completion

April 30, 2024

Last Updated

June 11, 2024

Record last verified: 2024-06

Data Sharing

IPD Sharing
Will not share

Locations